Received Mar 5, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | m4b34 | — |
a patient received the first 2 doses 6 months apart; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 76-year-old male patient who received HAB (Twinrix) (batch number m4b34) for prophylaxis. Previously administered products included Twinrix (received 1st dose on 01-JUN-2024). On 02-DEC-2024, the patient received the 2nd dose of Twinrix. On 02-DEC-2024, an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too long (Verbatim: a patient received the first 2 doses 6 months apart). The outcome of the drug dose administration interval too long was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 25-FEB-2025 The pharmacist contacted GlaxoSmithKline to report that a patient received the first 2 doses 6 months apart, which led to lengthening of vaccination schedule. The patient still has not received the third dose of Twinrix. They asked to know how to proceed. The vaccine administration facility was the same as primary reporter.